Pre-clinical vaccine evaluation

AI Summary

The Vaccine Development and Evaluation Centre (VDEC), a division of the UK Health Security Agency (UKHSA), provides comprehensive pre-clinical evaluation services to support vaccine and therapeutic development. Operating within a robust regulatory framework, the center maintains an enhanced quality management system compliant with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) standards. Their facilities are accredited for high-containment research at Biosafety Levels 3 and 4, adhering to the Advisory Committee on Dangerous Pathogens (ACDP) and Specified Animal Pathogen Order (SAPO) safety requirements. VDEC specializes in animal modeling, ranging from small rodents to non-human primates, and is currently focused on high-priority pathogens including avian influenza (H5N1), Respiratory Syncytial Virus (RSV), and antimicrobial-resistant Pseudomonas aeruginosa. The center also utilizes innovative 'organ-on-a-chip' technology to refine immune response studies and reduce animal reliance. As this document serves as a descriptive overview of VDEC’s capabilities and current initiatives, it does not detail specific inspection dates, regulatory violations, or mandatory corrective actions. Instead, it highlights the center's role in global health efforts, such as the 100 Days Mission, and invites collaboration from industry, academia, and government partners to ensure data integrity for regulatory submissions.